https://www.fiercebiotech.com/biotech/acelyrin-drops-two-izokibep-indications-and-slashes-staff-focus-looming-fight-amgen
Acelyrin drops izokibep, lays off 3rd of staff
Aug 13, 2024 - Despite promising phase 3 data, the California biotech is ending pursuit of two izokibep indications and laying off staff in favor of lonigutamab.
acelyrindropsizokibeplays3rd
https://www.biospace.com/acelyrin-inc-announces-long-term-32-week-data-from-the-phase-2b-trial-of-izokibep-in-hidradenitis-suppurativa-demonstrating-sustained-responses-and-deepening-clinical-benefit-improving-quality-of-life-for-patients
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis...
Mar 11, 2024 - ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in...